AI coach aims to close the hepatitis b treatment gap
NCT ID NCT07520123
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests an AI-powered assistant (Union-Agent) designed to encourage people with chronic hepatitis B who have been diagnosed but not yet treated to start antiviral medication. The study will enroll 2000 adults in China who are eligible for treatment but haven't started. The AI provides education, medication reminders, symptom tracking, and referral suggestions. The goal is to see if this approach can increase the number of patients who begin antiviral therapy within six months by at least 50% compared to current rates.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Intelligent-agent (Union-Agent) delivering education, reminders, follow-up, and referral suggestions
- What this could lead to
- If successful, this could show that an AI assistant can significantly increase the number of hepatitis B patients who start antiviral treatment, helping more people manage their condition.
- What could go wrong
- This is an early-stage study with no control group, so improvements may be due to other factors. The AI tool requires smartphone use, which may not work for all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC HEPATITIS B are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Department of Infectious Disease, Wuhan Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei, 430022, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a simple scan and blood test outsmart liver cancer?
- Can a new injection tame chronic hepatitis b?
- Double liver trouble: does having both hepatitis b and fatty liver speed up disease?
- A second punch against hepatitis b: interferon after RNA drugs may clear the virus
- Could common hepatitis b drugs damage kidneys? a study digs into the data
- Can fatty liver and hepatitis b together harm kidneys? a study digs into the data